CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS
Cologne, Germany, June 1, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.
CAP®Go Technology – Tailor-made glycosylation of recombinant proteins
With the CAP®Go technology, CEVEC addresses an increasing need in the pharmaceutical and biotechnology industries for the manufacturing of difficult to express therapeutic glycoproteins with tailor-made or fully human glycosylation patterns for significantly improved physicochemical and pharmacological properties.
CEVEC’s CAP®Go expression platform comprises a comprehensive portfolio of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities and allows for the recombinant production of a variety of complexly glycosylated proteins such as high molecular mass multimeric proteins including plasma proteins, coagulation factors, cytokines and antibodies.
In previous studies CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins. Depending on the selected CAP®Go cell line, the expressed protein showed: increased sialylation for improved half-life; homogenous, serum-like O-glycan structures and/or defined N-glycan antennarity, just to name a few. Therapeutic proteins expressed on conventional mammalian expression platforms like CHO or 293 cells, by contrast, often do not match the glycosylation and pharmacokinetic profiles of their plasma-purified counterparts. The CAP®Go technology provides a highly economic way to manufacture glyco-optimized proteins with up to 10fold higher yields than conventional cell lines and offers cost efficient large scale production.
“Our CAP®Go technology brings completely unique features to biopharmaceuticals, placing CEVEC at the leading edge of industrial protein manufacturing,” commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH “The CAP®Go expression platform is designed to manufacture normally ‘difficult to produce’ proteins, coagulation factors and other plasma derived substances as wanted and needed, addressing an increasing demand in the pharmaceutical and biotechnology industry.”
Privately held CEVEC is a global solution and service provider for the production of biopharmaceuticals based in Cologne, Germany. The Company’s core technologies, CAP®Go and CAP®GT are based on a unique human cell expression system.
The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express glycoproteins and provide authentic human post-translational modifications. CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins.
The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems.
Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology form one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP®Go and CAP®GT cells.
CEVEC Pharmaceuticals GmbH
Chief Executive Officer
T.:+49 221 46020800
MC Services AG
T.: +49 211 52925222